CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), will host nine CME-accredited satellite symposia adjunct to the 2019 ASCO (American Society of Clinical Oncology) Annual Meeting. These programs will be held at the Hilton Chicago and Hyatt Regency Chicago in Illinois from May 31 to June 2.
“We are once again grateful for the opportunity to present our satellite symposia at this year’s ASCO’s Annual Meeting in Chicago,” said Phil Talamo, president of PER®. “These nine programs cover a wide range of cancer topics and will feature a special liquid biopsies Medical Crossfire®, a melanoma tumor board, and a program that offers a mixed format of didactic lectures, panel discussions, and interactive clinical case studies of women’s cancers.”
The PER® satellite symposia lineup features:
- Leveraging Immunogenicity in Women’s Cancers: The Experts Weigh In on Current Evidence and Practical Guidance in Cervical and Endometrial Cancers, which will be held on Friday, May 31, from 7 to 9 p.m. at the Hilton Chicago in the International Ballroom South. The program will be chaired by Dr. Bradley J. Monk, professor and director of the division of gynecologic oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center. During this live activity, leading experts in the fields of cervical and endometrial cancers, will explore recent clinical developments through didactic presentation and case-based discussion. The faculty will also cover a wide range of topics, including the current landscape of treatment options for patients with cervical and endometrial cancers, recent advancements in understanding of the tumor microenvironment and how this influences immune response, the evolving role of immunotherapeutic for women’s cancers, and current and emerging biomarkers that may govern treatment selection for your patients. To register, click here.
- Show Me the Data™: Leveraging Evidence to Optimize Applications of Novel Therapies in AML, which will be held on Friday, May 31, from 7 to 9 p.m. at the Hyatt Regency Chicago in the Columbus A-F. The program will be chaired by Dr. Naval G. Daver, associate professor of the department of leukemia in the division of cancer medicine at The University of Texas MD Anderson Cancer Center. During this program, the expert faculty will cover key clinical decision points in the management of acute myeloid leukemia (AML). To register, click here.
- Medical Crossfire®: How to Use Liquid Biopsies in Oncology Care, which will be held on Friday, May 31, from 7 to 9 p.m. at the Hilton Chicago in the International Ballroom North. The program will be co-chaired by Dr. Benjamin Levy, clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and associate professor of oncology at John Hopkins University School of Medicine. During this cutting-edge Medical Crossfire®, both experts in liquid biopsies and internationally recognized specialists in lung, breast, and gastrointestinal cancers will come together provide attendees with the knowledge and confidence to bring state-of-the-art techniques to their practices. To register, click here.
- Leveraging Evolving Data Sets to Inform Treatment Decision-Making in Advanced RCC: An Expert Tumor Board Discussion, which will be held on Saturday, June 1, from 7 to 9 p.m. at the Hilton Chicago in the International Ballroom North. The program will be co-chaired by Dr. Robert A. Figlin, Steven Spielberg Family Chair in Hematology-Oncology, director of the division of hematology/oncology, deputy director of integrated oncology service line and a professor of medicine and biomedical sciences at Cedars-Sinai Medical Center. During this live program, internationally renowned experts in the treatment of patients with advanced renal cell carcinoma (RCC) will come together for an in-depth discussion on the clinical impact of recent and emerging trial data for monotherapies and combination approaches in RCC using a “real-world” tumor board format. A series of tightly integrated case presentations will illuminate RCC treatment decisions related to sequencing and switching based on patient and disease characteristics. Adverse events and their management will be a part of the discussion. Additionally, future directions in the field will be addressed and considered in the context of how recent developments and highly anticipated trials may soon shape future patient care. To register, click here.
- Melanoma Tumor Board: Matching Treatment to Patient, which will be held on Saturday, June 1, from 7 to 9 p.m. at the Hilton Chicago in the International Ballroom South. The program will be co-chaired by Dr. Jeffrey S. Weber, deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center. During this program, renowned international experts in melanoma treatment and clinical research will assess the clinical impact of recent and emerging trial data in melanoma. This activity will involve a series of case presentations integrating clinical trial data and will highlight melanoma treatment decisions related to current front-line and beyond therapies, treatment-related adverse events, and the impact of recent developments in the care of melanoma. To register, click here.
- Saturday Night Tumor Board: Applying the Evidence to Challenging Scenarios in Patients With NSCLC and EGFR Mutations, which will be held on Saturday, June 1, from 7 to 9 p.m. at the Hyatt Regency Chicago in the Columbus G-L. The program will be co-chaired by Dr. Mark G. Kris, attending physician in the thoracic oncology service and William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center. During this program, internationally renowned experts in the treatment of patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) gene will come together to help attendee’s leverage appropriate data sets in their clinical practice. Testing and choosing therapy along the disease continuum will be discussed, along with strategies to manage patients with brain metastases. Adverse event management and future directions in the field will also be addressed. To register, click here.
- Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy, and Beyond! which will be held on Saturday, June 1, from 7 to 9 p.m. at the Hyatt Regency Chicago in the Regency Ballroom C-D. The program will be co-chaired by Dr. Robert L. Coleman, professor in the department of gynecologic oncology and reproductive medicine at the University of Texas MD Anderson Cancer Center. During this program, a panel of experts in the management of ovarian cancer will present and assess the latest data on PARP inhibition and several other classes of therapy that are being explored in the field. The faculty will also discuss clinical implications of the data for contemporary practice in a case-based format. To register, click here.
- Navigating Treatment Sequencing in Pancreatic Cancer: Experts Paving the Road Toward Patient-Centric Care, which will be held on Sunday, June 2, from 7 to 9 p.m. Hilton Chicago in the International Ballroom South. The program will be co-chaired by Dr. Eileen M. O’ Reilly, associate director for clinical research, David M. Rubenstein Center for Pancreas Cancer at Memorial Sloan-Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College. During this interactive, case-based satellite symposium, the latest cutting-edge data will be presented within a framework of patient cases. The panel of experts in pancreatic cancer treatment and management will discuss evidence-based, guideline-recommended therapies and potential drug sequencing; the differential clinical profile of available treatments, including adverse event as well as pharmacodynamic and pharmacokinetic profiles; and the latest clinical trial developments in the evolving treatment landscape for pancreatic cancer. During this program, interactive questions interspersed throughout case presentations will give you the opportunity to identify and reflect on the optimal management of pancreatic cancer, and how to integrate emerging options into plans of care for your patients. To register, click here.
- Oncogenic Tumor Board in Advanced NSCLC: How Do You Strategize Treatment Planning for EGFR-Mutated and ALK-Rearranged Patients? which will be held on Sunday, June 2, from 7 to 9 p.m. Hilton Chicago in the International Ballroom North. The program will be co-chaired by Dr. David R. Gandara, professor of medicine in the division of hematology/oncology director of the thoracic oncology program, senior advisor to the director at the University of California Davis Comprehensive Cancer Center. During this program, the expert faculty will describe current and emerging strategies for the management of patients with EGFR-mutated and ALK-mutated forms of non–small cell lung cancer (NSCLC). Appropriate strategies for identification of EGFR and ALK mutations will be explored in this program, including current strategies for the most effective use of targeted therapies. Appropriate sequencing of agents, including in patients with the ALK mutation variant T790M, will be discussed, as well as best practices for management of patients who develop resistance to initial therapy. To register, click here.
Accredited by the Accreditation Council for Continuing Medical Education (ACCME), each PER session provides attendees with the opportunity to earn up to 2.0 AMA PRA Category 1 Credits™.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now furthers patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While continuing to expand into topics outside of oncology, PER® remains the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is part of the Cranbury, New Jersey-based MJH Associates Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.